The lived experiences of discomfort in women with Crohn's disease: a hermeneutic phenomenological study
Background: Discomfort in women with Crohn's disease is highly prevalent, even during
remission. However, these women's lived experiences of discomfort are largely unknown …
remission. However, these women's lived experiences of discomfort are largely unknown …
Virtual care in inflammatory bowel disease: Lessons learned in the CaNVAS-IBD Program
Geoffrey C. Nguyen MD PhD Peter Habashi NP-Adult MN Access to gastroenterologists who
specialize in treating inflammatory bowel disease (IBD) remains a concern across Canada …
specialize in treating inflammatory bowel disease (IBD) remains a concern across Canada …
Quality of Life in Patients With Inflammatory Bowel Disease: Importance of Psychological Symptoms
M Maria-Andriani, EC Fradelos, KY Lee, M Foteini… - Cureus, 2022 - search.proquest.com
Background Depressive, anxiety, and stress symptoms are prevalent in patients with
inflammatory bowel disease (IBD) and may negatively influence the disease course and …
inflammatory bowel disease (IBD) and may negatively influence the disease course and …
Identification and functional exploration of Ferroptosis and Immune Related Long Non-Coding RNA in Inflammatory bowel disease
Y Hu, S Sun, H Li - 2022 - researchsquare.com
Background: Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory
disease involving ileum, rectum and colon, including ulcerative colitis (UC) and Crohn's …
disease involving ileum, rectum and colon, including ulcerative colitis (UC) and Crohn's …
[HTML][HTML] The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: A Multi-Disciplinary Approach to Perianal Fistulizing Crohn's Disease
J Wiseman, T Chawla, F Morin… - Clinics in Colon and …, 2022 - ncbi.nlm.nih.gov
Perianal fistulizing Crohn's disease represents a severe phenotype associated with
significant morbidity. Patients with perianal fistulizing disease are more likely to have a …
significant morbidity. Patients with perianal fistulizing disease are more likely to have a …
Возрастные и гендерные аспекты воспалительных заболеваний кишечника в Республике Дагестан
СШ Ахмедханов, ГГ Абакарова… - Российский журнал …, 2022 - gastro-j.ru
Age-related and Gender Aspects of Inflammatory Bowel Diseases in the Republic of Dagestan
Page 1 68 www.gastro-j.ru Рос журн гастроэнтерол гепатол колопроктол 2022; 32(4) / Rus J …
Page 1 68 www.gastro-j.ru Рос журн гастроэнтерол гепатол колопроктол 2022; 32(4) / Rus J …
Methotrexate-loaded Microbubbles for Ultrasound-triggered Treatment of Inflammatory Bowel Disease
Y Ensminger - 2023 - search.proquest.com
Methotrexate (MTX) is a systemically injected immunomodulatory drug used to treat
inflammatory bowel disease (IBD). The goal of this thesis was to develop ultrasound …
inflammatory bowel disease (IBD). The goal of this thesis was to develop ultrasound …
[HTML][HTML] Budesonide Extended Release for Ulcerative Colitis: CADTH Health Technology Review
SD Khangura, C Spry - 2023 - europepmc.org
In 2017, the CADTH Canadian Drug Expert Committee recommended that budesonide
extended release (with multi-matrix system) not be reimbursed for the induction of remission …
extended release (with multi-matrix system) not be reimbursed for the induction of remission …
Advances in Nutritional Management of Pediatric Inflammatory Bowel Disease
W El-Matary - Nutrients, 2021 - mdpi.com
Crohn's disease (CD) and ulcerative colitis (UC) are chronic lifelong non-curable
inflammatory bowel diseases (IBD) of uncertain etiology with immune dysfunction likely …
inflammatory bowel diseases (IBD) of uncertain etiology with immune dysfunction likely …
[PDF][PDF] Budesonide Extended Release for Ulcerative Colitis
SD Khangura, C Spry - Canadian Journal of Health …, 2023 - canjhealthtechnol.ca
• In 2017, the CADTH Canadian Drug Expert Committee recommended that budesonide
extended release (with multi-matrix system) not be reimbursed for the induction of remission …
extended release (with multi-matrix system) not be reimbursed for the induction of remission …